{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T13:55:34Z","timestamp":1769090134343,"version":"3.49.0"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,12,12]]},"DOI":"10.7759\/cureus.20359","type":"journal-article","created":{"date-parts":[[2021,12,12]],"date-time":"2021-12-12T15:45:05Z","timestamp":1639323905000},"source":"Crossref","is-referenced-by-count":3,"title":["Milestones in Heart Failure: How Far We Have Come and How Far We Have Left to Go"],"prefix":"10.7759","author":[{"given":"Harini","family":"Gajjela","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iljena","family":"Kela","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chandra L","family":"Kakarala","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad","family":"Hassan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rishab","family":"Belavadi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sri Vallabh Reddy","family":"Gudigopuram","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ciri C","family":"Raguthu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Srimy","family":"Modi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ibrahim","family":"Sange","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0b013e31829e8807","article-title":"2013 ACCF\/AHA guideline for the management of heart failure: executive summary. A report of the American College of Cardiology Foundation\/American Heart Association Task Force on practice guidelines","volume":"128","author":"Yancy CW","year":"2013","unstructured":"Yancy CW, Jessup M, Bozkurt B, et al.. 2013 ACCF\/AHA guideline for the management of heart failure: executive summary. A report of the American College of Cardiology Foundation\/American Heart Association Task Force on practice guidelines. Circulation. 2013, 128:1810-52. 10.1161\/CIR.0b013e31829e8807","journal-title":"Circulation"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.320.7226.39","article-title":"ABC of heart failure. History and epidemiology","volume":"320","author":"Davis RC","year":"2000","unstructured":"Davis RC, Hobbs FD, Lip GY. ABC of heart failure. History and epidemiology. BMJ. 2000, 320:39-42. 10.1136\/bmj.320.7226.39","journal-title":"BMJ"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.483","article-title":"Epidemiology of heart failure: the prevalence of heart failure and ventricular dysfunction in older adults over time. A systematic review","volume":"18","author":"van Riet EE","year":"2016","unstructured":"van Riet EE, Hoes AW, Wagenaar KP, Limburg A, Landman MA, Rutten FH. Epidemiology of heart failure: the prevalence of heart failure and ventricular dysfunction in older adults over time. A systematic review. Eur J Heart Fail. 2016, 18:242-52. 10.1002\/ejhf.483","journal-title":"Eur J Heart Fail"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1161\/HHF.0b013e318291329a","article-title":"Forecasting the impact of heart failure in the United States. A policy statement from the American Heart Association","volume":"6","author":"Heidenreich PA","year":"2013","unstructured":"Heidenreich PA, Albert NM, Allen LA, et al.. Forecasting the impact of heart failure in the United States. A policy statement from the American Heart Association. Circ Heart Fail. 2013, 6:606-19. 10.1161\/HHF.0b013e318291329a","journal-title":"Circ Heart Fail"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2020.11.012","article-title":"2021 ACC\/AHA key data elements and definitions for heart failure: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Clinical Data Standards for Heart Failure)","volume":"77","author":"Bozkurt B","year":"2021","unstructured":"Bozkurt B, Hershberger RE, Butler J, et al.. 2021 ACC\/AHA key data elements and definitions for heart failure: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Clinical Data Standards for Heart Failure). J Am Coll Cardiol. 2021, 77:2053-150. 10.1016\/j.jacc.2020.11.012","journal-title":"J Am Coll Cardiol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2008.11.013","article-title":"2009 focused update incorporated into the ACC\/AHA 2005 guidelines for the diagnosis and management of heart failure in adults: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines developed in collaboration with the International Society for Heart and Lung Transplantation","volume":"53","author":"Hunt SA","year":"2009","unstructured":"Hunt SA, Abraham WT, Chin MH, et al.. 2009 focused update incorporated into the ACC\/AHA 2005 guidelines for the diagnosis and management of heart failure in adults: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines developed in collaboration with the International Society for Heart and Lung Transplantation. J Am Coll Cardiol. 2009, 53:e1-e90. 10.1016\/j.jacc.2008.11.013","journal-title":"J Am Coll Cardiol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1161\/01.HYP.0000216794.24161.8c","article-title":"Amino-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide. Biomarkers for mortality in a large community-based cohort free of heart failure","volume":"47","author":"McKie PM","year":"2006","unstructured":"McKie PM, Rodeheffer RJ, Cataliotti A, et al.. Amino-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide. Biomarkers for mortality in a large community-based cohort free of heart failure. Hypertension. 2006, 47:874-80. 10.1161\/01.HYP.0000216794.24161.8c","journal-title":"Hypertension"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.hfc.2021.01.002","article-title":"Biomarkers in heart failure: clinical insights","volume":"17","author":"Salzano A","year":"2021","unstructured":"Salzano A, D'Assante R, Israr MZ, et al.. Biomarkers in heart failure: clinical insights. Heart Fail Clin. 2021, 17:223-43. 10.1016\/j.hfc.2021.01.002","journal-title":"Heart Fail Clin"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.114.302589","article-title":"The autonomic nervous system and heart failure","volume":"114","author":"Florea VG","year":"2014","unstructured":"Florea VG, Cohn JN. The autonomic nervous system and heart failure. Circ Res. 2014, 114:1815-26. 10.1161\/CIRCRESAHA.114.302589","journal-title":"Circ Res"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.4330\/wjc.v12.i8.373","article-title":"Sympathetic nervous system activation and heart failure: current state of evidence and the pathophysiology in the light of novel biomarkers","volume":"12","author":"Borovac JA","year":"2020","unstructured":"Borovac JA, D'Amario D, Bozic J, Glavas D. Sympathetic nervous system activation and heart failure: current state of evidence and the pathophysiology in the light of novel biomarkers. World J Cardiol. 2020, 12:373-408. 10.4330\/wjc.v12.i8.373","journal-title":"World J Cardiol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1038\/nrcardio.2016.163","article-title":"Neurohormonal activation in heart failure with reduced ejection fraction","volume":"14","author":"Hartupee J","year":"2017","unstructured":"Hartupee J, Mann DL. Neurohormonal activation in heart failure with reduced ejection fraction. Nat Rev Cardiol. 2017, 14:30-8. 10.1038\/nrcardio.2016.163","journal-title":"Nat Rev Cardiol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1161\/01.res.37.3.318","article-title":"Direct effect of beta-adrenergic stimulation on renin release by the rat kidney slice in vitro","volume":"37","author":"Weinberger MH","year":"1975","unstructured":"Weinberger MH, Aoi W, Henry DP. Direct effect of beta-adrenergic stimulation on renin release by the rat kidney slice in vitro. Circ Res. 1975, 37:318-24. 10.1161\/01.res.37.3.318","journal-title":"Circ Res"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2017.07.091","article-title":"Renin-angiotensin-aldosterone (RAAS): the ubiquitous system for homeostasis and pathologies","volume":"94","author":"Patel S","year":"2017","unstructured":"Patel S, Rauf A, Khan H, Abu-Izneid T. Renin-angiotensin-aldosterone (RAAS): the ubiquitous system for homeostasis and pathologies. Biomed Pharmacother. 2017, 94:317-25. 10.1016\/j.biopha.2017.07.091","journal-title":"Biomed Pharmacother"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchf.2012.10.002","article-title":"Heart failure","volume":"1","author":"Braunwald E","year":"2013","unstructured":"Braunwald E. Heart failure. JACC Heart Fail. 2013, 1:1-20. 10.1016\/j.jchf.2012.10.002","journal-title":"JACC Heart Fail"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1038\/nature06798","article-title":"Tackling heart failure in the twenty-first century","volume":"451","author":"Mudd JO","year":"2008","unstructured":"Mudd JO, Kass DA. Tackling heart failure in the twenty-first century. Nature. 2008, 451:919-28. 10.1038\/nature06798","journal-title":"Nature"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1038\/nm1582","article-title":"MicroRNA-133 controls cardiac hypertrophy","volume":"13","author":"Car\u00e8 A","year":"2007","unstructured":"Car\u00e8 A, Catalucci D, Felicetti F, et al.. MicroRNA-133 controls cardiac hypertrophy. Nat Med. 2007, 13:613-8. 10.1038\/nm1582","journal-title":"Nat Med"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.15252\/embj.201387605","article-title":"MiR-133 promotes cardiac reprogramming by directly repressing Snai1 and silencing fibroblast signatures","volume":"33","author":"Muraoka N","year":"2014","unstructured":"Muraoka N, Yamakawa H, Miyamoto K, et al.. MiR-133 promotes cardiac reprogramming by directly repressing Snai1 and silencing fibroblast signatures. EMBO J. 2014, 33:1565-81. 10.15252\/embj.201387605","journal-title":"EMBO J"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1126\/science.1139089","article-title":"Control of stress-dependent cardiac growth and gene expression by a microRNA","volume":"316","author":"van Rooij E","year":"2007","unstructured":"van Rooij E, Sutherland LB, Qi X, Richardson JA, Hill J, Olson EN. Control of stress-dependent cardiac growth and gene expression by a microRNA. Science. 2007, 316:575-9. 10.1126\/science.1139089","journal-title":"Science"},{"key":"ref19","article-title":"Sir James Black and propranolol. The role of the basic sciences in the history of cardiovascular pharmacology","volume":"24","author":"Stapleton MP","year":"1997","unstructured":"Stapleton MP. Sir James Black and propranolol. The role of the basic sciences in the history of cardiovascular pharmacology. Tex Heart Inst J. 1997, 24:336-42.","journal-title":"Tex Heart Inst J"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.5694\/j.1326-5377.1994.tb127604.x","article-title":"Beta-blockers","volume":"161","author":"Louis WJ","year":"1994","unstructured":"Louis WJ, Louis SN, Krum H. Beta-blockers. Med J Aust. 1994, 161:555-7. 10.5694\/j.1326-5377.1994.tb127604.x","journal-title":"Med J Aust"},{"key":"ref21","doi-asserted-by":"crossref","DOI":"10.1097\/00005344-199627003-00002","article-title":"From alpha and beta to I1. An overview of sympathetic receptors involved in blood pressure control targets for drug treatment","volume":"27","author":"Van Zwieten PA","year":"1996","unstructured":"Van Zwieten PA. From alpha and beta to I1. An overview of sympathetic receptors involved in blood pressure control targets for drug treatment. J Cardiovasc Pharmacol. 1996, 27:5-10.","journal-title":"J Cardiovasc Pharmacol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-biochem-060614-033910","article-title":"The molecular basis of g protein-coupled receptor activation","volume":"87","author":"Weis WI","year":"2018","unstructured":"Weis WI, Kobilka BK. The molecular basis of g protein-coupled receptor activation. Annu Rev Biochem. 2018, 87:897-919. 10.1146\/annurev-biochem-060614-033910","journal-title":"Annu Rev Biochem"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(98)11181-9","article-title":"The cardiac insufficiency bisoprolol study II (CIBIS-II): a randomised trial","volume":"353","author":"Investigators CI","year":"1999","unstructured":"Investigators CI. The cardiac insufficiency bisoprolol study II (CIBIS-II): a randomised trial. Lancet. 1999, 353:9-13. 10.1016\/S0140-6736(98)11181-9","journal-title":"Lancet"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(99)04440-2","article-title":"Effect of metoprolol cr\/xl in chronic heart failure: metoprolol cr\/xl randomised intervention trial in-congestive heart failure (MERIT-HF)","volume":"353","author":"Merit-HF Study Group","year":"1999","unstructured":"Merit-HF Study Group. Effect of metoprolol cr\/xl in chronic heart failure: metoprolol cr\/xl randomised intervention trial in-congestive heart failure (MERIT-HF). Lancet. 1999, 353:2001-7. 10.1016\/S0140-6736(99)04440-2","journal-title":"Lancet"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1161\/01.cir.0000035653.72855.bf","article-title":"Effect of carvedilol on the morbidity of patients with severe chronic heart failure. Results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study","volume":"106","author":"Packer M","year":"2002","unstructured":"Packer M, Fowler MB, Roecker EB, et al.. Effect of carvedilol on the morbidity of patients with severe chronic heart failure. Results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. Circulation. 2002, 106:2194-9. 10.1161\/01.cir.0000035653.72855.bf","journal-title":"Circulation"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001841.pub3","article-title":"First-line drugs for hypertension","volume":"4","author":"Wright JM","year":"2018","unstructured":"Wright JM, Musini VM, Gill R. First-line drugs for hypertension. Cochrane Database Syst Rev. 2018, 4:CD001841. 10.1002\/14651858.CD001841.pub3","journal-title":"Cochrane Database Syst Rev"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198706043162301","article-title":"Effects of enalapril on mortality in severe congestive heart failure","volume":"316","author":"The Consensus Trial Study Group","year":"1987","unstructured":"The Consensus Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. N Engl J Med. 1987, 316:1429-35. 10.1056\/NEJM198706043162301","journal-title":"N Engl J Med"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199108013250501","article-title":"Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure","volume":"325","author":"Yusuf S","year":"1991","unstructured":"Yusuf S, Pitt B, Davis CE, Hood WB, Cohn JN. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991, 325:293-302. 10.1056\/NEJM199108013250501","journal-title":"N Engl J Med"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa010713","article-title":"A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure","volume":"345","author":"Cohn JN","year":"2001","unstructured":"Cohn JN, Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med. 2001, 345:1667-75. 10.1056\/NEJMoa010713","journal-title":"N Engl J Med"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1016\/s0735-1097(02)02304-5","article-title":"Effects of valsartan on morbidity and mortality in patients with heart failure not receiving angiotensin-converting enzyme inhibitors","volume":"40","author":"Maggioni AP","year":"2002","unstructured":"Maggioni AP, Anand I, Gottlieb SO, Latini R, Tognoni G, Cohn JN. Effects of valsartan on morbidity and mortality in patients with heart failure not receiving angiotensin-converting enzyme inhibitors. J Am Coll Cardiol. 2002, 40:1414-21. 10.1016\/s0735-1097(02)02304-5","journal-title":"J Am Coll Cardiol"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(00)02213-3","article-title":"Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial\u2014the losartan heart failure survival study ELITE II","volume":"355","author":"Pitt B","year":"2000","unstructured":"Pitt B, Poole-Wilson PA, Segal R, et al.. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial\u2014the losartan heart failure survival study ELITE II. Lancet. 2000, 355:1582-7. 10.1016\/s0140-6736(00)02213-3","journal-title":"Lancet"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(03)14284-5","article-title":"Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-alternative trial","volume":"362","author":"Granger CB","year":"2003","unstructured":"Granger CB, McMurray JJ, Yusuf S, et al.. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-alternative trial. Lancet. 2003, 362:772-6. 10.1016\/S0140-6736(03)14284-5","journal-title":"Lancet"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(03)14285-7","article-title":"Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-preserved trial","volume":"362","author":"Yusuf S","year":"2003","unstructured":"Yusuf S, Pfeffer MA, Swedberg K, et al.. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-preserved trial. Lancet. 2003, 362:777-81. 10.1016\/S0140-6736(03)14285-7","journal-title":"Lancet"},{"key":"ref34","unstructured":"US Food and Drug Administration. Novel drug approvals for 2015. (2015). Accessed. October 2, 2021: https:\/\/www.fda.gov\/drugs\/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products\/novel-dr...."},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20092092","article-title":"ARNi: a novel approach to counteract cardiovascular diseases","volume":"20","author":"Volpe M","year":"2019","unstructured":"Volpe M, Rubattu S, Battistoni A. ARNi: a novel approach to counteract cardiovascular diseases. Int J Mol Sci. 2019, 20:2092. 10.3390\/ijms20092092","journal-title":"Int J Mol Sci"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1007\/s00395-004-0457-8","article-title":"The natriuretic peptides","volume":"99","author":"Baxter GF","year":"2004","unstructured":"Baxter GF. The natriuretic peptides. Basic Res Cardiol. 2004, 99:71-5. 10.1007\/s00395-004-0457-8","journal-title":"Basic Res Cardiol"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1042\/CS20030366","article-title":"Combined inhibition of angiotensin II and endothelin suppresses the brain natriuretic peptide response to developing heart failure","volume":"106","author":"Rademaker MT","year":"2004","unstructured":"Rademaker MT, Charles CJ, Espiner EA, Frampton CM, Nicholls MG, Richards AM. Combined inhibition of angiotensin II and endothelin suppresses the brain natriuretic peptide response to developing heart failure. Clin Sci (Lond). 2004, 106:569-76. 10.1042\/CS20030366","journal-title":"Clin Sci (Lond)"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1016\/0196-9781(88)90024-1","article-title":"Identification of protease 3.4. 24.11 as the major atrial natriuretic factor degrading enzyme in the rat kidney","volume":"9","author":"Sonnenberg JL","year":"1988","unstructured":"Sonnenberg JL, Sakane Y, Jeng AY, et al.. Identification of protease 3.4. 24.11 as the major atrial natriuretic factor degrading enzyme in the rat kidney. Peptides. 1988, 9:173-80. 10.1016\/0196-9781(88)90024-1","journal-title":"Peptides"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1177\/0091270009343932","article-title":"Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual-acting angiotensin receptor-neprilysin inhibitor (ARNi)","volume":"50","author":"Gu J","year":"2010","unstructured":"Gu J, Noe A, Chandra P, et al.. Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual-acting angiotensin receptor-neprilysin inhibitor (ARNi). J Clin Pharmacol. 2010, 50:401-14. 10.1177\/0091270009343932","journal-title":"J Clin Pharmacol"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.115","article-title":"Baseline characteristics and treatment of patients in prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure trial (PARADIGM-HF)","volume":"16","author":"McMurray JJ","year":"2014","unstructured":"McMurray JJ, Packer M, Desai AS, et al.. Baseline characteristics and treatment of patients in prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure trial (PARADIGM-HF). Eur J Heart Fail. 2014, 16:817-25. 10.1002\/ejhf.115","journal-title":"Eur J Heart Fail"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.118.039331","article-title":"Clinical outcomes in patients with acute decompensated heart failure randomly assigned to sacubitril\/valsartan or enalapril in the PIONEER-HF trial","volume":"139","author":"Morrow DA","year":"2019","unstructured":"Morrow DA, Velazquez EJ, DeVore AD, et al.. Clinical outcomes in patients with acute decompensated heart failure randomly assigned to sacubitril\/valsartan or enalapril in the PIONEER-HF trial. Circulation. 2019, 139:2285-8. 10.1161\/CIRCULATIONAHA.118.039331","journal-title":"Circulation"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1908655","article-title":"Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction","volume":"381","author":"Solomon SD","year":"2019","unstructured":"Solomon SD, McMurray JJ, Anand IS, et al.. Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction. N Engl J Med. 2019, 381:1609-20. 10.1056\/NEJMoa1908655","journal-title":"N Engl J Med"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1016\/j.cnc.2019.04.003","article-title":"Surgical approaches in heart failure","volume":"31","author":"Falls C","year":"2019","unstructured":"Falls C, Kolodziej AR. Surgical approaches in heart failure. Crit Care Nurs Clin North Am. 2019, 31:267-83. 10.1016\/j.cnc.2019.04.003","journal-title":"Crit Care Nurs Clin North Am"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure","volume":"341","author":"Pitt B","year":"1999","unstructured":"Pitt B, Zannad F, Remme WJ, et al.. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med. 1999, 341:709-17. 10.1056\/NEJM199909023411001","journal-title":"N Engl J Med"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1009492","article-title":"Eplerenone in patients with systolic heart failure and mild symptoms","volume":"364","author":"Zannad F","year":"2011","unstructured":"Zannad F, McMurray JJ, Krum H, et al.. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011, 364:11-21. 10.1056\/NEJMoa1009492","journal-title":"N Engl J Med"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1313731","article-title":"Spironolactone for heart failure with preserved ejection fraction","volume":"370","author":"Pitt B","year":"2014","unstructured":"Pitt B, Pfeffer MA, Assmann SF, et al.. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med. 2014, 370:1383-92. 10.1056\/NEJMoa1313731","journal-title":"N Engl J Med"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman B","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM, et al.. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015, 373:2117-28. 10.1056\/NEJMoa1504720","journal-title":"N Engl J Med"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal B","year":"2017","unstructured":"Neal B, Perkovic V, Mahaffey KW, et al.. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017, 377:644-57. 10.1056\/NEJMoa1611925","journal-title":"N Engl J Med"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1016\/j.pcad.2019.07.003","article-title":"Diabetes, heart failure, and renal dysfunction: the vicious circles","volume":"62","author":"Braunwald E","year":"2019","unstructured":"Braunwald E. Diabetes, heart failure, and renal dysfunction: the vicious circles. Prog Cardiovasc Dis. 2019, 62:298-302. 10.1016\/j.pcad.2019.07.003","journal-title":"Prog Cardiovasc Dis"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2019.00111","article-title":"Devices in heart failure patients\u2014who benefits from ICD and CRT?","volume":"6","author":"Breitenstein A","year":"2019","unstructured":"Breitenstein A, Steffel J. Devices in heart failure patients\u2014who benefits from ICD and CRT?. Front Cardiovasc Med. 2019, 6:111. 10.3389\/fcvm.2019.00111","journal-title":"Front Cardiovasc Med"},{"key":"ref51","article-title":"Outpatient treatment of systolic heart failure","volume":"70","author":"McConaghy JR","year":"2004","unstructured":"McConaghy JR, Smith SJ. Outpatient treatment of systolic heart failure. Am Fam Phys. 2004, 70:2157-64.","journal-title":"Am Fam Phys"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.2174\/1574884708666131117125508","article-title":"A practical guide for the treatment of symptomatic heart failure with reduced ejection fraction (HFrEF)","volume":"11","author":"Reed BN","year":"2015","unstructured":"Reed BN, Sueta CA. A practical guide for the treatment of symptomatic heart failure with reduced ejection fraction (HFrEF). Curr Cardiol Rev. 2015, 11:23-32. 10.2174\/1574884708666131117125508","journal-title":"Curr Cardiol Rev"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.4070\/kcj.2017.0030","article-title":"Current drug therapy in chronic heart failure: the new guidelines of the European Society of Cardiology (ESC)","volume":"47","author":"Berliner D","year":"2017","unstructured":"Berliner D, Bauersachs J. Current drug therapy in chronic heart failure: the new guidelines of the European Society of Cardiology (ESC). Korean Circ J. 2017, 47:543-54. 10.4070\/kcj.2017.0030","journal-title":"Korean Circ J"},{"key":"ref54","article-title":"Heart failure: a class review of pharmacotherapy","volume":"42","author":"Shah A","year":"2017","unstructured":"Shah A, Gandhi D, Srivastava S, Shah KJ, Mansukhani R. Heart failure: a class review of pharmacotherapy. P T. 2017, 42:464-72.","journal-title":"P T"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.161.3.342","article-title":"Treatment of congestive heart failure. Guidelines for the primary care physician and the heart failure specialist","volume":"161","author":"Gomberg-Maitland M","year":"2001","unstructured":"Gomberg-Maitland M, Baran DA, Fuster V. Treatment of congestive heart failure. Guidelines for the primary care physician and the heart failure specialist. Arch Intern Med. 2001, 161:342-52. 10.1001\/archinte.161.3.342","journal-title":"Arch Intern Med"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/77309-milestones-in-heart-failure-how-far-we-have-come-and-how-far-we-have-left-to-go","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:33:50Z","timestamp":1707507230000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/77309-milestones-in-heart-failure-how-far-we-have-come-and-how-far-we-have-left-to-go"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,12]]},"references-count":55,"URL":"https:\/\/doi.org\/10.7759\/cureus.20359","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12,12]]}}}